Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418444 | 0.88 | S1PR1 (0.49) | S1PR1CYP2C9S1PR5 | |
| SCHEMBL1293530 | 0.87 | S1PR1 (0.57) | S1PR1CYP2C9CYP2D6 | |
| SCHEMBL1293234 | 0.84 | S1PR1 (0.73) | S1PR1CYP2C9S1PR5CYP2D6 | |
| SCHEMBL3422112 | 0.84 | S1PR1 (0.75) | S1PR1CYP2C9S1PR5CYP2D6 | |
| SCHEMBL12102472 | 0.84 | S1PR1 (0.57) | S1PR1CYP2C9 | |
| SCHEMBL3418767 | 0.83 | S1PR1 (0.57) | S1PR1CYP2C9S1PR5CYP2D6 | |
| SCHEMBL3418754 | 0.82 | S1PR1 (0.52) | S1PR1CYP2C9S1PR5CYP2D6 | |
| SCHEMBL3418740 | 0.82 | S1PR1 (0.59) | S1PR1CYP2C9S1PR5CYP2D6 | |
| SCHEMBL3419916 | 0.82 | S1PR1 (0.63) | S1PR1CYP2C9S1PR5CYP2D6 | |
| SCHEMBL3418408 | 0.82 | S1PR1 (0.45) | S1PR1CYP2C9S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | S1PR1 1075/4885CYP2C9 598/4885S1PR5 930/4885 |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885CYP2C9 3708/4885S1PR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.